Financial Data and Key Metrics Changes - Annual net sales for 2025 grew by $3 billion to $28.4 billion, representing a 12% increase compared to the prior year, with 11% organic growth driven by strong demand from existing customers and new customer signings [10][12] - Adjusted EBITDA was $3.5 billion, a 3% increase year-over-year, reflecting robust sales but partially offset by higher costs of goods due to tariffs and investments in the business [10][18] - Free cash flow for the full year was $1.3 billion, impacted by legal settlements and increased tariffs compared to previous years [19] Business Line Data and Key Metrics Changes - The Medline Brand segment achieved $3.7 billion in net sales for Q4, up 12%, and $13.7 billion for the full year, up 10% [12][10] - Surgical Solutions net sales for Q4 were $1.7 billion, up 12%, driven by strong growth in surgical kitting and other OR products [13] - Supply Chain Solutions segment delivered $4.1 billion in Q4, up 18%, supported by new customer implementations and existing customer growth [15] Market Data and Key Metrics Changes - U.S. Acute Care sales grew 16% in Q4 to $5.3 billion and 12% for the full year to $19.5 billion, driven by new Prime Vendor customers and solid same-store sales growth [16] - U.S. Non-Acute sales grew 12% in Q4 to $1.9 billion and 11% for the full year to $7 billion, supported by strong existing customer growth [16] - International sales grew 12% in Q4 to $537 million and 11% for the full year to $2 billion, driven by volume growth in Canada and Europe [16] Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and financial flexibility post-IPO to invest in future growth and enhance its distribution network through automation and technology [5][9] - Medline is focusing on expanding its product portfolio and enhancing supply chain solutions, including the implementation of AI-powered technologies [9][10] - The company is committed to maintaining a $1 billion annual target for new Prime Vendor signings, reflecting its strategy to capitalize on market conditions and customer needs [46] Management's Comments on Operating Environment and Future Outlook - Management noted that healthcare is facing a crisis of complexity, with hospitals focusing on stabilizing reimbursement profiles and seeking value-driven partnerships [31] - There is an expectation of continued strong sales growth in 2026, with organic sales growth projected in the range of 8%-9% [20] - The tariff environment remains fluid, and management is evaluating the impact of recent tariff changes while maintaining a cautious approach [21][55] Other Important Information - The company ended the year with a successful IPO, raising over $7 billion, which strengthened its financial position and reduced net leverage from 4.9x to 3.1x [9][20] - Capital expenditures for the full year were $447 million, focusing on capacity expansion and technology upgrades [19] Q&A Session Summary Question: What are hospital customers' priorities for 2026? - Management highlighted that hospitals are focused on stabilizing reimbursement profiles and seeking value-driven partnerships due to ongoing complexities in healthcare [31][32] Question: How was the guidance for 2026 constructed? - The guidance reflects confidence in achieving strong organic sales growth driven by new customer signings and same-store sales growth, despite potential moderation due to external factors [39][40] Question: What is the outlook for Prime Vendor contract wins? - Management confirmed a commitment to $1 billion in new Prime Vendor signings for 2026, with favorable market conditions expected to support this goal [46][48] Question: What is the impact of tariffs on future earnings? - The company expects a $200 million tariff headwind in 2026, with ongoing evaluations of the tariff landscape to inform future strategies [21][55] Question: Are there any changes in market dynamics due to competitor transitions? - Management noted that market conditions remain similar to 2025, with opportunities arising from competitors' strategic shifts and ongoing consolidation in healthcare [61][62]
Medline(MDLN) - 2025 Q4 - Earnings Call Transcript